Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anti-cancer therapy

Leigha Rowbottom¹, Jordan Stinson², Rachel McDonald¹, Urban Emmenegger³, Susanna Cheng³, Julia Lowe¹, Angie Giotis², Paul Cheon¹, Ronald Chow¹, Mark Pasetka², Nemica Thavarajah¹, Natalie Pulenzas³, Edward Chow¹, Carlo DeAngelis²

¹Rapid Response Radiotherapy Program, Department of Radiation Oncology, ²Department of Pharmacy, ³Department of Medical Oncology, 4Department of Endocrinology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Correspondence to: Dr. Carlo DeAngelis, PhD. Department of Pharmacy, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. Email: Carlo.DeAngelis@sunnybrook.ca.

Background: Corticosteroids are used adjuvant to certain chemotherapy regimens, either as an antiemetic, to reduce other side effects, or to enhance cancer treatment. Additionally, they are frequently used for symptom control in cancer patients with end stage disease. Corticosteroid use may induce hyperglycemia in approximately 20-50% of patients, which may negatively affect patient outcomes.

Objective: To determine the frequency of blood glucose monitoring in patients with and without diabetes receiving continuous corticosteroids with chemotherapy, and to determine the incidence of treatment-emergent abnormal blood glucose levels and steroid-induced diabetes mellitus (DM).

Methods: A retrospective review was conducted for 30 genitourinary (GU) cancer patients who were treated with continuous oral corticosteroids as part of their chemotherapy regimen. The Canadian Diabetes Association (CDA) criterion for diagnosis of diabetes was applied to categorize patients into two distinct groups, patients with diabetes and patients without diabetes. This categorization was made based on glucose measurements completed prior to commencement of corticosteroid therapy. Glucose monitoring was defined as receiving a laboratory blood glucose test before first chemotherapy administration along with a test within a week of each subsequent treatment cycle. The CDA criteria for diagnosis of pre-diabetes and diabetes was used to classify glucose levels as hyperglycemic.

Results: The mean incidence of blood glucose monitoring was 19% and 76% in patients with diabetes and patients without diabetes, respectively. Approximately, 40% of patients with diabetes required an adjustment to their diabetes management and a further 20% required hospitalization. Fifteen patients without diabetes received a fasting blood glucose test, of which 40% had abnormal blood glucose results; half of these fell into the pre-diabetic range and half in the diabetic range. Ten patients without diabetes were tested for diabetes using the CDA criteria for diabetes diagnosis during or after their chemotherapy, of which 30% developed diabetes.

Conclusions: In order to optimize patient care, blood glucose levels should be monitored in all patients receiving continuous oral corticosteroids as part of their chemotherapy. Future studies should be conducted prospectively to determine the most effective manner of monitoring in order to implement screening guidelines and avoid unnecessary morbidity.

Keywords: Corticosteroid-induced diabetes; cancer; hyperglycemia

Submitted Apr 09, 2015. Accepted for publication Apr 16, 2015.
doi: 10.3978/j.issn.2224-5820.2015.04.07
View this article at: http://dx.doi.org/10.3978/j.issn.2224-5820.2015.04.07
Introduction

Since their effectiveness as antiemetics was first shown 30 years ago, corticosteroids have been used in conjunction with chemotherapy to prevent side effects such as acute or delayed nausea and vomiting (1,2). Currently, corticosteroids are used adjuvant to certain chemotherapy regimens, either as an antiemetic, to reduce other side effects, or for additional therapeutic benefit (3). Corticosteroids are also frequently dispensed to patients with end stage disease who may no longer be eligible for anti-cancer therapies as a method of symptom control (3). However, corticosteroids, such as dexamethasone, prednisone, and hydrocortisone, have been known to cause elevations in blood glucose levels in both patients with and without diabetes (4-6).

Hyperglycemia may lead to acute complications or adverse events (AEs), such as dehydration, increased risk of infection, ketoacidosis, and acute hyperglycaemic syndrome (7). It has also been shown to be a risk factor for cancer-related death in men, and was found to have a significant negative effect on survival in patients with small cell lung and breast carcinomas (7,8). As such, blood glucose levels may need to be monitored in patients both with and without diabetes (4-6).

Methods

Patients with genitourinary (GU) cancers treated at the Sunnybrook Odette Cancer Centre in Toronto, Canada from July to December 2013 with at least one chemotherapy cycle inclusive of a corticosteroid used both for premedication and continuously throughout the treatment period were eligible for the study. Patient medical records were retrospectively reviewed to extract patient demographics, chemotherapy treatment details, corticosteroid treatment dates and dosages, and diabetes status prior to start of treatment. All laboratory blood glucose tests [either fasting plasma glucose (FPG), or random plasma glucose (RPG)], or HbA1c, were extracted from on- and accessible off-site records and were analyzed applying the Canadian Diabetes Association (CDA) criteria for diabetes mellitus (DM) diagnosis and pre-diabetes diagnosis (9). RPG and FPG results were organized into the four graded categories set forth by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Home blood glucose tests were not included due to the retrospective nature of this study. Glucose monitoring was defined as receiving a blood test before the first chemotherapy administration as well as a test within a week of each subsequent treatment cycle. At the time of this review, there were no guidelines for glucose monitoring in patients receiving corticosteroids with chemotherapy. All tests were ordered at the discretion of the patients’ oncologist. We also undertook a literature review (Table 1).

This study was approved by the Research Ethics Board prior to commencement.

Results

Patient demographics

A total of 30 GU male patients were eligible, of which 37% (n=11) had diabetes and 63% (n=19) did not have diabetes prior to receiving corticosteroid treatment. Of the 30 GU patients, 26 were prostate cancer (PC) patients, and four were bladder cancer patients. The median body mass index (BMI) was 29.5 kg/m$^2$ for patients with diabetes and 26.5 kg/m$^2$ for those without diabetes. The median ages were 74 and 69 years, respectively. All patients received docetaxel chemotherapy with oral prednisone 5 mg (continuous) and dexamethasone 8 mg the day prior to and the day of chemotherapy treatment. The median incidence of blood glucose monitoring was 13% and 75% in patients with and without diabetes, respectively. The incidence of hyperglycemia among patients in each group is summarized in Table 2.

Patients without pre-existing diabetes

Hyperglycemia resulted in hospitalization in 23% (n=7) of monitored patients. Thirteen patients without diabetes were tested with RPG, of which 15% (n=3) had a RPG greater than 27.8 mmol/L. Two of these patients were admitted to hospital, and then subsequently discharged with diabetic medications. The other patient presented with polyuria and polydipsia and was admitted to hospital with hyperosmolar hyperglycemia due to the addition of dexamethasone to their medication regime. The patient was started on insulin, educated on home glucose monitoring and discharged. Later, the patient was readmitted to hospital with
<table>
<thead>
<tr>
<th>First author [year]</th>
<th>Details</th>
<th>Patient characteristics</th>
<th>Outcome</th>
<th>Conclusion</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee SY [2014]</td>
<td>80 lymphoma patients treated with CHOP regimen, excluded patients with history of DM.</td>
<td>32.5% developed GC-IH.</td>
<td>Significant factors associated with GC-IH were: age ≥60 years, HbA1c levels &gt;6.1%, BMI &gt;30 kg/m$^2$, prednisolone administration prior to chemotherapy, history of hypertension or hypertension at admission, and the presence of metabolic syndrome.</td>
<td>Findings suggest need for plasma glucose monitoring in patients receiving CHOP with no history of DM.</td>
<td>(10)</td>
</tr>
<tr>
<td>Hong YJ [2014]</td>
<td>Reviewed 206 metastatic colorectal patients treated with palliative chemotherapy from March 2000 to December 2012.</td>
<td>Patients grouped based on mean glucose levels (group 1, low to group 4, high). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months respectively.</td>
<td>No statistical difference in overall survival.</td>
<td>Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs.</td>
<td>(11)</td>
</tr>
<tr>
<td>Kotila TR [2013]</td>
<td>Report of four patients who developed DM during treatment with prednisolone for haematological disorders despite a negative history of DM.</td>
<td>Mean age of the patients was 55 years and DM was diagnosed by FPG after a cumulative steroid dose of 500-1,800 mg.</td>
<td>Development of DM does not appear to be dose dependent or related to history of DM in the patient or family.</td>
<td>Recommending baseline and frequent FPG in patients with chemotherapy and concurrent corticosteroids.</td>
<td>(12)</td>
</tr>
<tr>
<td>Harris D [2013]</td>
<td>Monitored patients treated with GC for brain tumors or metastasis, for lymphomas, or patients undergoing bone marrow transplants with random glucose tests.</td>
<td>90 patients screened: 55.6% men; hyperglycemia in 58.9% and DM-range hyperglycemia (glucose &gt;11.1 mmol/L) in 18.9%.</td>
<td>No correlation with traditional DM risk factors (age, sex, BMI, personal/family history of DM).</td>
<td>GC-induced hyperglycemia is common and is not predictable. Recommending screening in all cancer patients 4-6 h after first GC dose.</td>
<td>(14)</td>
</tr>
</tbody>
</table>

Table 1 (continued)
<table>
<thead>
<tr>
<th>First author</th>
<th>Details</th>
<th>Patient characteristics</th>
<th>Outcome</th>
<th>Conclusion</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gonzalez-Gonzalez JG [2013]</td>
<td>Monitored 35 non-diabetic individuals with newly diagnosed lymphoblastic leukemia or NHL on high dose GC therapy.</td>
<td>40.6% were found to have diabetes after first week. 66.6% returned to normal after 8 weeks. Pre-diabetes occurred in 34.3% and diabetes occurred in 34.3%.</td>
<td>Continuous GC dosing had higher incidence of fasting hyperglycemia.</td>
<td>High-dose prednisone for 2-3 months produced an elevated incidence of diabetes, usually with mild hyperglycemia occurring between the second and fourth week, normalizing spontaneously in all cases.</td>
<td>(15)</td>
</tr>
<tr>
<td>Luo J [2012]</td>
<td>Review of 342 inpatients with newly diagnosed NSCLC.</td>
<td>Examined effects of fasting glucose levels at time of diagnosis on overall survival.</td>
<td>Diabetes was associated with higher risk of all-cause mortality in patients with NSCLC.</td>
<td>Concluded that effective control of diabetes or hyperglycemia may improve prognosis in NSCLC patients.</td>
<td>(8)</td>
</tr>
<tr>
<td>Brunello A [2011]</td>
<td>Review of NHL and PC patients treated from January 1999 to September 2006 who received chemotherapy plus steroids.</td>
<td>349 patients (162 NHL, 187 PC) of which 47% of NHL and 5% of PC experienced grade 4 HemT and 79 NHL and 90 PC patients experienced grade 3-4 non-hematological toxicities, including neutropenia, fatigue, thromboembolic event. 44% of NHL and 68% of PC patients had abnormal glycemia at baseline. 70% of NHL and 92% PC had abnormal glycemia while on treatment.</td>
<td>Positive correlation between baseline hyperglycemia and grade 4 HemT. Multivariate correlation between average glycemia during chemotherapy and overall severe toxicity was significant.</td>
<td>Multivariate correlation between average glycemia during chemotherapy and overall toxicity was significant for PC patients. However, it was unclear if hyperglycemia correlates with HemT for PC patients.</td>
<td>(16)</td>
</tr>
<tr>
<td>Gannon C [2010]</td>
<td>Case report of female with steroid-induced hyperglycemia.</td>
<td>Reduced steroid dose slightly and patient no longer required insulin.</td>
<td>Recommending testing blood glucose 2 h after meal and single dose insulin in the morning to treat SI-DM.</td>
<td></td>
<td>(17)</td>
</tr>
<tr>
<td>Krone CA [2005]</td>
<td>Measured glycated haemoglobin in two patient groups, those with active disease and those in remission.</td>
<td>Statistically significant lower average blood glucose in those in remission.</td>
<td>Hyperglycemia can impair the actions of ascorbic acid, damage immune function, and have negative impact on cancer survival.</td>
<td>Recommend lifestyle changes including diet, physical activity, and ascorbic acid supplementation adjunct to cancer therapy.</td>
<td>(18)</td>
</tr>
</tbody>
</table>

CHOP, chemotherapy used to treat non-Hodgkin lymphoma; DM, diabetes mellitus; GC-IH, glucocorticoid-induced hyperglycemia; HbA1c, glycosylated hemoglobin; BMI, body mass index; AEs, adverse events; FPG, fasting plasma glucose; GC, glucocorticoid; NSCLC, non-small cell lung cancer; NHL, non-Hodgkin lymphoma; PC, prostate cancer; HemT, hematological toxicity; SI-DM, steroid induced-diabetes mellitus.
Rowbottom et al. Glucose monitoring in cancer patients on corticosteroids

© Annals of Palliative Medicine. All rights reserved. www.amepc.org/apm


© Annals of Palliative Medicine. All rights reserved. www.amepc.org/apm

Insulin was added to his diabetes regimen along with home blood glucose monitoring.

**Discussion**

The effects of corticosteroids are observed within hours of administration and are generally dose dependent, impacting RPG levels more so than FPG levels (19). High doses and prolonged use of corticosteroids may result in side effects such as hyperglycemia, increased insulin resistance, dyslipidemia, osteoporosis, adrenal suppression, cardiovascular disease (CVD), Cushing’s syndrome, psychological disturbances, and immunosuppression (19-21). Acute hyperglycemia is known to impair immune function and wound healing, which represents a risk to cancer patients by lengthening hospital stays and increasing risk of all-cause mortality (14,21). The results of this study identified potential areas of improvement for the management of corticosteroid-associated hyperglycemia. The findings of the study may help in guiding the formation of screening guidelines to be implemented at the centre in order to optimize patient care. To prevent complications and potential AEs in cancer patients receiving corticosteroid therapy best practice guidelines should include parameters for glycemic control.

A study by Yoo et al. (4) examined 632 patients who received docetaxel chemotherapy and were screened for hyperglycemia (defined as 2 RPG levels >11.1 mmol/L) and for infectious events requiring antibiotics. Two separate blood glucose tests with levels above 11.1 mmol/L will conclude the patient has diabetes, not merely hyperglycemia (9). The study determined the incidence of hyperglycemia in all patients was 13.8% and risk factors for hyperglycemia were being overweight or obese, and previous DM. On the other hand, the study determined corticosteroid dose intensity and density, as well as the chemotherapy administration schedule were not risk factors for hyperglycemia, making it difficult to identify high risk patients based on treatment regimen. An observational cohort study conducted by Harris et al. screened 90 patients undergoing chemotherapy plus concurrent corticosteroid treatment for brain tumors or metastases, for lymphomas, or as part of bone marrow transplants (14). Patients were monitored with RPG tests and hyperglycemia was found in 59% of all patients and 19% tested in the diabetic range. The investigators found no correlation between risk factors for diabetes and the individuals who experienced hyperglycemia, thus recommending all cancer patients were screened 4-6 hours

<table>
<thead>
<tr>
<th>Blood glucose levels</th>
<th>Monitored patients, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diabetic</td>
</tr>
<tr>
<td>Random plasma glucose (mmol/L)</td>
<td>9 (100.0)</td>
</tr>
<tr>
<td>8.0-10.9</td>
<td>9 (100.0)</td>
</tr>
<tr>
<td>11.0-14.9</td>
<td>5 (55.6)</td>
</tr>
<tr>
<td>15.0-27.8</td>
<td>5 (55.6)</td>
</tr>
<tr>
<td>&gt;27.8</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fasting plasma glucose (CTCAE grades) (mmol/L)</th>
<th>9</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1: ULN-8.9</td>
<td>7 (77.8)</td>
<td>4 (28.6)</td>
</tr>
<tr>
<td>Grade 2: 8.9-13.9</td>
<td>7 (77.8)</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Grade 3: 13.9-27.8</td>
<td>1 (11.1)</td>
<td>—</td>
</tr>
<tr>
<td>Grade 4: &gt;27.8 or acidosis</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

CTCAE, Common Terminology Criteria for Adverse Events; ULN, upper limit of normal confirmed via the CTCAE.

Table 2 Incidence of hyperglycemia

Elevated blood glucose levels and cholangitis; the patient subsequently declined rapidly and expired.

A further 15% (n=3) of patients without diabetes had a RPG result in the range of 15.0-27.8 mmol/L. Two of these patients were admitted to hospital; one was admitted with acute multiple organ failure, possibly due to tumor lysis syndrome, as well as with concurrent severe metabolic acidosis. He expired in hospital. The other patient was admitted for hyperglycemia and discharged with a reduced dexamethasone dose to improve glycemic control. One patient without diabetes required a change in prednisone dosing to achieve better glycemic control.

**Patients with pre-existing diabetes**

For patients with diabetes with a RPG result above 11.0 mmol/L, 40% (n=4) required a change in their diabetes management and 20% (n=2) required hospitalizations where hyperglycemia was noted as a comorbidity impacting hospital stay. One patient admitted for sepsis and poor urinary control was noted to have inadequate glycemic control resulting in an endocrinology consult and adjustment of insulin dosage. The other patient was admitted for acute kidney injury due to urinary retention and was discharged home without modification of his diabetes regimen. One week post-corticosteroid commencement an additional individual was seen in the emergency department with a FPG result of 26.7 mmol/L.
post steroid administration. Thus it may be difficult to
determine high risk patients for developing corticosteroid-
induced hyperglycemia (C-IH) and hard to prevent if
typical risk factors for diabetes are not consistent in this
circumstance. It may be surmised that if the individual
tests are normal after initial dosing, then they may not
require additional monitoring. The aforementioned cancer
population tended to receive higher doses of corticosteroids
than the GU cancer patients in our study. This may explain
the higher incidence of hyperglycemia. Thus, any screening
recommendations may need to be modified for GU cancer
patients.

The Joint British Diabetes Association (JBDA) recently
published guidelines for inpatient care, which state that
predisposing factors for steroid induced hyperglycemia
include pre-existing type 1 or 2 diabetes, obesity, family
history of diabetes, as well as others (22). It is essential
that risk factors for corticosteroid-induced diabetes are
identified so that high risk patients, who may require more
rigorous monitoring, can be determined. The risk factors
proposed by Yoo et al. (4) and the JBDA may be applicable
in this approach.

Brady et al. (5) conducted a literature review on C-IH
and determined that hyperglycemia occurs in hospitalized
cancer patients irrespective of diabetic history. The study
concluded that all corticosteroid recipients should be
monitored through clinical observation and blood glucose
tests where appropriate. Two other studies previously
determined that C-IH is common in both patients with
and without diabetes [odds ratio of 1.5 to 2.5 and 1.36 to
2.31 for developing glucocorticoid-induced hyperglycemia
(GC-IH) in patients treated with a glucocorticoid (GC),
respectively] and determined that total GC dose and
duration of use were strong predictors of GC induced
diabetes, along with age and BMI (6, 23). Furthermore, even
acute elevations in blood glucose levels may be associated
with adverse outcomes (6). Both studies concluded that
steroids can result in significant clinical implications that
require early recognition and management in patients both
with and without diabetes (6).

A recent study by Derweesh et al. (24) recommended
blood glucose screening 48 hours after GC initiation
followed by screening every 3-6 months for the first year
then annually thereafter. This may represent a more
feasible model for monitoring patients on long term low
dose corticosteroid use, such as PC patients undergoing
chemotherapy or androgen synthesis inhibitor therapy
with abiraterone. However, due to the high incidence of
hyperglycemia and hospitalizations observed in this cohort,
more rigorous and frequent testing may be required for
chronic high dose corticosteroids. Liu et al. (19) recommended
all patients have extensive baseline examination including
medical history, body weight, height, and blood pressure
to determine risk factors or conditions that may be
exacerbated by corticosteroid use. A blood glucose test
should be ordered before initiating corticosteroid therapy,
if initial results are abnormal at baseline then home glucose
monitoring is recommended (19). The CDA recommends
that any individual commencing corticosteroid therapy
be monitored for the subsequent 48 hours and glycemic
control maintained, regardless of pre-existing diabetes
or not (9). If individuals test above the recommended
target range (6-10 mmol/L) then interventions may be
required and individuals should continue to be screened.
In particular, males with metastatic castrate resistant PC
treated with corticosteroids should be closely monitored
for the presence of steroid associated toxicities, including
hyperglycemia, with the possibility of adjusting the dose in
certain affected patients (25).

Brunello et al. (16) reviewed 349 non-Hodgkin lymphoma
(NHL) (n=162) and PC (n=187) patients treated with a
chemotherapy regimen inclusive of a steroid. Abnormal
glucose levels at baseline were found in 44% and 68% of
NHL and PC patients, respectively. Over the course of
treatment, dysglycemia was observed in 70% of patients
with NHL and 92% of patients with PC. The study found
no association between hyperglycemia and survival nor
hospitalization rate (16). A similar result was determined
by Hong et al. (11) who reviewed 206 metastatic colorectal
patients segregated into four graded categories according
to mean blood glucose results (using all available tests).
Increasing mean blood glucose was associated with more
infection related AEs, but not shorter survival. Various
other studies have suggested that pre-existing diabetes
in addition to cancer increases all-cause mortality and
cancer recurrence in various cancer types (7,8,14,26,27).
In a recent meta-analysis, Barone et al. (26) determined
that patients with pre-existing diabetes with endometrial,
breast, or colorectal cancer had a 41% increased risk of
cancer mortality compared to individuals without diabetes.
Therefore, it is essential that proper diabetes management
is part of the standard of care for cancer patients with diabetes
or pre-diabetes to ensure best standard of practice and
optimal patient outcomes. The studies reporting on C-IH
have discrepant results regarding effect on survival, yet tend
to be unanimous that hyperglycemia can lead to AEs. Future
studies should be conducted to determine the extent of the corticosteroid adverse effects on patient survival.

Patients with pre-existing diabetes who receive corticosteroids as part of their cancer treatment may require a change in their diabetes management and consideration of the benefits and risks before commencement of steroid therapy. Duan et al. (28) hypothesized that hyperglycemia contributes to malignant growth by inhibiting apoptosis, inducing cell proliferation, aiding metastasis, and facilitating chemotherapy resistance. Individuals receiving corticosteroids require some form of monitoring to prevent acute AEs, as well as long term complications in non-palliative patients. Patients who develop corticosteroid-induced diabetes may require endocrinologist assessment and commencement of anti-hyperglycemics.

In our study, a cohort of 30 cancer patients treated with a chemotherapy regimen inclusive of a corticosteroid were retrospectively evaluated for frequency of blood glucose monitoring and prevalence of hyperglycemic events. Our study may underestimate the clinical significance and incidence of abnormal blood glucose levels as not all patients were monitored consistently. However, due to the retrospective nature of our study we were not able to determine the incidence of home capillary blood glucose monitoring, and if any individual treatment or monitoring modifications occurred. It is also unknown if patients were symptomatic when blood testing occurred, or if any intervention was conducted by the physician ordering the glucose test. The Joint British Diabetes Societies recently came out with recommended monitoring guidelines for steroid-induced diabetes, as well as recommendations for glycemic control in hospitalized patients and outpatients. The guidelines recommend for patients without diabetes that monitoring occurs once per day with the frequency of testing related to the glucose level measured. For patients with diabetes, testing should occur 4 times per day (22). If both patient groups exceed 12 mmol/L on two separate occasions then treatment should be dispensed (22). The guideline provides a well-structured monitoring regime, yet will require extensive patient education and resources to supply all patients who take steroids with home capillary glucose monitoring kits. Additionally, a study conducted by Zanders et al. showed that adherence to glucose-lowering drug treatment declines following a cancer diagnosis (29).

The introduction of more medications and treatment regimens may result in overall lower adherence to drug treatment. The CTCAE uses FPG for the grading of hyperglycemic events, which we applied to RPG tests in this study. It must also be noted that FPG test results may be erroneous due to confounding factors, such as patient non-compliance to fasting.

Conclusions

Corticosteroids are an essential component of the current standard of care for treatment of certain types of cancer. The chronic use of corticosteroids may exacerbate existing diabetic status and worsen treatment outcomes for cancer patients. Patients who are prescribed a corticosteroid should be monitored in order to prevent adverse effects and to be able to intervene if they occur. Future studies should ascertain the optimal method of monitoring in patients undergoing chronic corticosteroid use; one that is feasible and is able to prevent corticosteroid-induced AEs. Investigations should also determine the threshold for clinical significance and the effect on cancer outcomes from abnormal blood glucose levels. To optimize patient care and outcomes patients receiving corticosteroids should receive adequate support and monitoring in order to prevent the development of corticosteroid-induced diabetes and its associated complications.

Acknowledgements

We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.

Disclosure: The authors declare no conflict of interest.

References